The WasteWatcher: The Staff Blog of Citizens Against Government Waste

340B

Drug Prices - The Council of Economic Advisers and Trump Administration Weigh In

Last Friday, on February 9, 2018, the White House Council of Economic Advisers released a 30-page report on, “Reforming Biopharmaceutical Pricing at Home and Abroad.”  There is enough in the report to please or give heartburn to all the players in the pharmaceutical distribution chain but, there are many significant ideas that policy makers should and will consider.  President Trump’s administration has already done so for its 2019 budget proposal, which will be discussed briefly in this blog.

Taxpayers and Patients Win First Round on 340B Drug Discount Rule

Citizens Against Government Waste (CAGW) discussed in its November 7, 2017 WasteWatcher blog, a Centers for Medicare and Medicaid Services (CMS) final rule for Medicare Part B that will lower costs to taxpayers and Medicare beneficiaries for certain outpatient pharmaceuticals purchased under the 340B drug discount program.

New CMS Rule Will Help Reduce Drug Costs

On Wednesday, November 1, 2017, the Centers for Medicare and Medicaid Services (CMS) issued a new rule that will lower costs to taxpayers and Medicare beneficiaries for certain outpatient pharmaceuticals purchased under the 340B drug discount program.

Sign Up for Email Updates!Click Here!

View Archives

Posts by Author

Posts by Tag

Big Government (151) Waste (74) Obamacare (71) Healthcare (70) Budget (68) Congress (62) Uncategorized (56) Telecommunications (50) Technology (45) Internet (44) Debt (43) Deficit (43)